Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Treasury Shares (2021 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Treasury Shares for 5 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $11.0 million, compared with a TTM value of $11.0 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $11.0 million, changed 0.0% over the prior year.
  • Treasury Shares was $1.6 million for Q4 2025 at Zevra Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.8 million in Q4 2024 and bottomed at $320161.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.0 million, with a median of $909953.0 recorded in 2022.
  • The sharpest move saw Treasury Shares skyrocketed 167.8% in 2022, then changed 0.0% in 2024.
  • Year by year, Treasury Shares stood at $2.8 million in 2021, then surged by 167.8% to $7.5 million in 2022, then surged by 45.74% to $11.0 million in 2023, then changed by 0.0% to $11.0 million in 2024, then changed by 0.0% to $11.0 million in 2025.
  • Business Quant data shows Treasury Shares for ZVRA at $11.0 million in Q4 2025, $11.0 million in Q3 2025, and $11.0 million in Q2 2025.